MedTrace Logo

Glucose Metabolism During Hemodialysis

NCT01800188 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2013-11-19

No results posted yet for this study

Summary

Disturbed glucose metabolism is a common feature of patients with end-stage renal disease (ESRD). Several hormones responsible of a stable blood glucose including insulin, glucagon, and the gastrointestinal insulinotropic hormones Glucagon-like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Peptide (GIP) are elevated in patients with ESRD. These hormones are all medium sized peptides which theoretically makes them removable during high efficient hemodialysis. A significant removal could have consequences for the treatment of patients with diabetes and ESRD.

The purpose of this study is to determine whether insulin, glucagon, GLP-1 and GIP are cleared during high efficient hemodialysis and hemodiafiltration. The investigators hypothesize that a significant amount of these hormones is removed during hemodialysis and to a larger extend during hemodiafiltration.

Conditions

  • ESRD

Interventions

PROCEDURE

Hemodialysis

A 4 hour hemodialysis with a standardized liquid meal after one hour

PROCEDURE

Hemodiafiltration

A 4 hour hemodiafiltration with a standardized liquid meal after one hour

PROCEDURE

Meal test

A 3 hour standardized liquid meal test without dialysis

Sponsors & Collaborators

  • Bo Feldt-Rasmussen

    lead OTHER

Principal Investigators

  • Bo Feldt-Rasmussen, MD DMSc · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01800188 on ClinicalTrials.gov